FindTrial
Sign In

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00348023
Enrollment
Unknown
Registered
2006-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2007-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Brief summary

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

Interventions

DRUGBimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%

Sponsors

Innovative Medical
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* · Male or female \> 18 years of age * Diagnosis of primary open-angle glaucoma or ocular hypertension * Untreated IOP \> 18 mm Hg in each eye at the baseline evaluation * Ability to provide informed consent and likely to complete all study visits

Exclusion criteria

* · Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication * Uncontrolled systemic disease * Active ocular disease other than POAG or ocular hypertension * Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted) * History of intraocular surgery within the last 3 months * Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026